257 related articles for article (PubMed ID: 18759657)
1. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter.
Selting K; Waldrep JC; Reinero C; Branson K; Gustafson D; Kim DY; Henry C; Owen N; Madsen R; Dhand R
J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):255-68. PubMed ID: 18759657
[TBL] [Abstract][Full Text] [Related]
2. Targeted combined aerosol chemotherapy in dogs and radiologic toxicity grading.
Selting K; Essman S; Reinero C; Branson KR; Henry CJ; Owen N; Guntur VP; Waldrep JC; Kim DY; Dhand R
J Aerosol Med Pulm Drug Deliv; 2011 Feb; 24(1):43-8. PubMed ID: 21166584
[TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacokinetic and tissue distribution investigation of sustained-release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs.
Yin JX; Wei Z; Xu JJ; Sun ZQ
Cancer Chemother Pharmacol; 2015 Sep; 76(3):525-36. PubMed ID: 26183605
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
5. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer.
Sugiyama T; Kumagai S; Nishida T; Ushijima K; Matsuo T; Yakushiji M; Hyon SH; Ikada Y
Anticancer Res; 1998; 18(4B):2837-42. PubMed ID: 9713471
[TBL] [Abstract][Full Text] [Related]
6. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice.
Júnior AD; Mota LG; Nunan EA; Wainstein AJ; Wainstein AP; Leal AS; Cardoso VN; De Oliveira MC
Life Sci; 2007 Jan; 80(7):659-64. PubMed ID: 17141809
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer.
Xie Y; Aillon KL; Cai S; Christian JM; Davies NM; Berkland CJ; Forrest ML
Int J Pharm; 2010 Jun; 392(1-2):156-63. PubMed ID: 20363303
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
Vadiei K; Siddik ZH; Khokhar AR; al-Baker S; Sampedro F; Perez-Soler R
Cancer Chemother Pharmacol; 1992; 30(5):365-9. PubMed ID: 1505075
[TBL] [Abstract][Full Text] [Related]
9. Aerosolized chemotherapy.
Gagnadoux F; Hureaux J; Vecellio L; Urban T; Le Pape A; Valo I; Montharu J; Leblond V; Boisdron-Celle M; Lerondel S; Majoral C; Diot P; Racineux JL; Lemarie E
J Aerosol Med Pulm Drug Deliv; 2008 Mar; 21(1):61-70. PubMed ID: 18518832
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
11. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
12. Hyperthermic isolated regional perfusion with CDDP for bone and soft-tissue sarcoma of the lower limb: pharmacokinetics, thermal dose, toxicity, and feasibility.
Abe S; Tokizaki T; Miki Y; Tateishi A; Ogawa K; Nakano H; Matsushita T
Cancer Chemother Pharmacol; 2005 Jul; 56(1):55-62. PubMed ID: 15791455
[TBL] [Abstract][Full Text] [Related]
13. A novel drug delivery system of intraperitoneal chemotherapy for peritoneal carcinomatosis using gelatin microspheres incorporating cisplatin.
Gunji S; Obama K; Matsui M; Tabata Y; Sakai Y
Surgery; 2013 Nov; 154(5):991-9. PubMed ID: 24008088
[TBL] [Abstract][Full Text] [Related]
14. Endovascular lung perfusion using high-dose cisplatin: uptake and DNA adduct formation in an animal model.
Brown DB; Ma MK; Battafarano RJ; Naidu S; Pluim D; Zamboni WC; McLeod HL
Oncol Rep; 2004 Jan; 11(1):237-43. PubMed ID: 14654932
[TBL] [Abstract][Full Text] [Related]
15. Miniaturized nebulization catheters: a new approach for delivery of defined aerosol doses to the rat lung.
Tronde A; Baran G; Eirefelt S; Lennernäs H; Bengtsson UH
J Aerosol Med; 2002; 15(3):283-96. PubMed ID: 12396416
[TBL] [Abstract][Full Text] [Related]
16. Nonuniform alteration of cis-diamminedichloroplatinum(II) tissue distribution in dogs with whole body hyperthermia.
Riviere JE; Page RL; Rogers RA; Chang SK; Dewhirst MW; Thrall DE
Cancer Res; 1990 Apr; 50(7):2075-80. PubMed ID: 2317796
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
[TBL] [Abstract][Full Text] [Related]
18. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.
Stathopoulos GP; Boulikas T; Vougiouka M; Deliconstantinos G; Rigatos S; Darli E; Viliotou V; Stathopoulos JG
Oncol Rep; 2005 Apr; 13(4):589-95. PubMed ID: 15756428
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.
Johnsson A; Olsson C; Nygren O; Nilsson M; Seiving B; Cavallin-Stahl E
Cancer Chemother Pharmacol; 1995; 37(1-2):23-31. PubMed ID: 7497593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
